ILLUMINATE-A, une étude de phase 3 du lumasiran, un ARNi thérapeutique expérimental, chez les enfants et les adultes atteints d’hyperoxalurie primaire de type 1
Sander F. Garrelfs(Emma Kinderziekenhuis), John C. Lieske(Mayo Clinic), Shabir Moochhala(The Royal Free Hospital), William van’t Hoff(Great Ormond Street Hospital), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), W. O’Riordan, Gesa Schalk, Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), Maya Koren‐Michowitz(Jacksonville University), John M. Gansner(Brigham and Women's Hospital), Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Daniel G. Fuster(University of Bern), Eva Šimková(Université Claude Bernard Lyon 1), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Pushkal Garg(Université Paris-Sud), Daniella Magen(Université Claude Bernard Lyon 1), J. W. Groothoff(Emma Kinderziekenhuis), Sally A. Hulton(Birmingham Children's Hospital), J. Lu(Alnylam Pharmaceuticals (United States)), Tracy L. McGregor(Université Claude Bernard Lyon 1), Kristin Meliambro(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Burosumab Therapy in Children with X-Linked Hypophosphatemia
|New England Journal of Medicine|2018|479
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|410